Are Alternative Donors Really Still "Alternative?"

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 10, 2014, Pages 1463-1464

  Kanakry, Christopher G ^a   Luznik, Leo ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THYMOCYTE ANTIBODY; HLA ANTIGEN; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ALLOGENIC BONE MARROW TRANSPLANTATION; CANCER PATIENT; CHRONIC GRAFT VERSUS HOST DISEASE; CORD BLOOD STEM CELL TRANSPLANTATION; DISEASE FREE SURVIVAL; ENGRAFTMENT; GRAFT VERSUS HOST REACTION; HLA MATCHED SIBLING DONOR; HLA MATCHED UNRELATED DONOR; HLA MATCHING; HLA TYPING; HODGKIN DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA RELAPSE; NOTE; ORGAN DONOR; PROGRESSION FREE SURVIVAL; REDUCED INTENSITY CONDITIONING; SIBLING; UMBILICAL CORD BLOOD; UNRELATED DONORS; WHOLE BODY RADIATION; ALLOTRANSPLANTATION; BONE MARROW TRANSPLANTATION; GENE EXPRESSION; GENETICS; GRAFT VS HOST DISEASE; HAPLOTYPE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; MORTALITY; RECURRENT DISEASE; SURVIVAL ANALYSIS;

BONE MARROW TRANSPLANTATION; CYCLOSPORINE; GENE EXPRESSION; GRAFT VS HOST DISEASE; HAPLOTYPES; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; RECURRENCE; SIBLINGS; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS; UNRELATED DONORS;

EID: 84912085338     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.07.029     Document Type: Note

References (28)

1. Ottinger H., Grosse-Wilde M., Schmitz A., Grosse-Wilde H. Immunogenetic marrow donor search for 1012 patients: a retrospective analysis of strategies, outcome and costs. Bone Marrow Transplant 1994, 14(Suppl 4):S34-S38.
2. Brunstein C.G., Fuchs E.J., Carter S.L., et al. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood 2011, 118:282-288.
3. Aversa F., Martelli M.F., Velardi A. Haploidentical hematopoietic stem cell transplantation with a megadose T-cell-depleted graft: harnessing natural and adaptive immunity. Semin Oncol 2012, 39:643-652.
4. Chang Y.J., Huang X.J. Haploidentical bone marrow transplantation without T-cell depletion. Semin Oncol 2012, 39:653-663.
5. Luznik L., O'Donnell P.V., Fuchs E.J. Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation. Semin Oncol 2012, 39:683-693.
6. Raiola A.M., Dominietto A., di Grazia C., et al. Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts. Biol Blood Marrow Transplant 2014, 20:1573-1579.
7. Szydlo R., Goldman J.M., Klein J.P., et al. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. JClin Oncol 1997, 15:1767-1777.
8. Arora M., Weisdorf D.J., Spellman S.R., et al. HLA-identical sibling compared with 8/8 matched and mismatched unrelated donor bone marrow transplant for chronic phase chronic myeloid leukemia. JClin Oncol 2009, 27:1644-1652.
9. Ringden O., Pavletic S.Z., Anasetti C., et al. The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. Blood 2009, 113:3110-3118.
10. Petersdorf E.W., Mickelson E.M., Anasetti C., et al. Effect of HLA mismatches on the outcome of hematopoietic transplants. Curr Opin Immunol 1999, 11:521-526.
11. Duggan P., Booth K., Chaudhry A., et al. Unrelated donor BMT recipients given pretransplant low-dose antithymocyte globulin have outcomes equivalent to matched sibling BMT: a matched pair analysis. Bone Marrow Transplant 2002, 30:681-686.
12. Saber W., Opie S., Rizzo J.D., et al. Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia. Blood 2012, 119:3908-3916.
13. Yakoub-Agha I., Mesnil F., Kuentz M., et al. Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy. JClin Oncol 2006, 24:5695-5702.
14. Gupta V., Tallman M.S., He W., et al. Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis. Blood 2010, 116:1839-1848.
15. Eapen M., Rubinstein P., Zhang M.J., et al. Outcomes of transplantation ofunrelated donor umbilical cord blood and bone marrow in childrenwith acute leukaemia: a comparison study. Lancet 2007, 369:1947-1954.
16. Brunstein C.G., Gutman J.A., Weisdorf D.J., et al. Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. Blood 2010, 116:4693-4699.
17. Marks D.I., Woo K.A., Zhong X., et al. Unrelated umbilical cord blood transplant for adult acute lymphoblastic leukemia in first and second complete remission: a comparison with allografts from adult unrelated donors. Haematologica 2014, 99:322-328.
18. Rocha V., Cornish J., Sievers E.L., et al. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood 2001, 97:2962-2971.
19. Rodrigues C.A., Rocha V., Dreger P., et al. Alternative donor hematopoietic stem cell transplantation for mature lymphoid malignancies after reduced-intensity conditioning regimen: similar outcomes with umbilical cord blood and unrelated donor peripheral blood. Haematologica 2014, 99:370-377.
20. Peffault de Latour R., Brunstein C.G., et al. Similar overall survival using sibling, unrelated donor, and cord blood grafts after reduced-intensity conditioning for older patients with acute myelogenous leukemia. Biol Blood Marrow Transplant 2013, 19:1355-1360.
21. Anasetti C., Beatty P.G., Storb R., et al. Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. Hum Immunol 1990, 29:79-91.
22. Luznik L., O'Donnell P.V., Symons H.J., et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008, 14:641-650.
23. Munchel A., Kesserwan C., Symons H.J., et al. Nonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamide. Pediatr Rep 2011, 3(Suppl 2):e15.
24. Bashey A., Zhang X., Sizemore C.A., et al. T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. JClin Oncol 2013, 31:1310-1316.
25. Burroughs L.M., O'Donnell P.V., Sandmaier B.M., et al. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 2008, 14:1279-1287.
26. Patriarca F., Luznik L., Medeot M., et al. Experts' considerations on HLA-haploidentical stem cell transplantation. Eur J Haematol 2014 Mar 24, 10.1111/ejh.12322.
27. Luznik L., Bolanos-Meade J., Zahurak M., et al. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood 2010, 115:3224-3230.
28. Kanakry C.G., O'Donnell P.V., Furlong T., et al. Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning. JClin Oncol 2014, 10.1200/JCO.2013.54.0625.